Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gepar-Duo: ADOC vs AC-DOC in Operable Breast Cancer
NCT00793377Phase 3Completed
- Sponsor
- GBG Forschungs
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of doxorubicin and docetaxel in breast cancer (2 arms), sponsored by GBG Forschungs. Primary endpoint: Pathological Locoregional Complete Tumor Response at 3 years. Status: completed.
02
Drugs
doxorubicindocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00793377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00793377.